查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2070303

全球腫瘤分子診斷市場：機會與策略展望（至2035年）

Oncology Molecular Diagnostics Global Market Opportunities And Strategies To 2035
出版日期: | 出版商: The Business Research Company | 英文 396 Pages | 商品交期: 2-10個工作天內

價格
簡介目錄

2020 年全球腫瘤分子診斷市場價值為 32.26 億美元，預計到 2025 年將以超過 11.0% 的複合年成長率成長。

腫瘤分子診斷是指一系列診斷測試和技術，這些測試和技術分析遺傳物質、蛋白質和其他分子生物標記物，以檢測、表徵和後續觀察。這些診斷方法由腫瘤學家、病理學家和實驗室技術人員等醫療專業人員使用，以識別與各種類型癌症相關的特定突變、基因表現和分子特徵。

腫瘤分子診斷市場由從事腫瘤分子診斷業務的企業（包括機構、自僱和合夥企業）所產生的收入所構成，這些業務涵蓋癌症治療的各個階段，包括早期檢測、診斷、預後、治療方法選擇以及疾病進展和夥伴關係的監測。腫瘤分子診斷常用於患者出現疑似癌症症狀、常規身體檢查或根據腫瘤基因特徵選擇標靶治療時。

醫療基礎設施擴建

從歷史上看，腫瘤分子診斷市場的發展一直受到醫療基礎設施擴張的推動。隨著各國政府和醫療機構不斷增加對醫療體系建設、診斷設施擴建和先進醫療技術普及的投入，諸如次世代定序（NGS）、液態生物檢體和基於生物標記的檢測等分子診斷解決方案的應用日益廣泛，從而支持癌症的早期發現、精準診斷和個性化治療方案的製定。例如，2022年5月，澳洲政府負責公共政策和醫療體系發展的官方機構報告稱，2022-2023會計年度醫療體系投資達到創紀錄的1320億美元，預計到2025-2026會計年度將增至1400億美元，未來四年總投資額將達到5370億美元。這凸顯了各國日益重視加強醫療基礎建設和擴大先進醫療服務的覆蓋範圍。因此，在這段歷史時期，腫瘤分子診斷市場的發展一直受到醫療基礎設施擴張的推動。

物聯網 (IoT)、智慧基礎設施和互聯生態系統

腫瘤分子診斷市場的領導者正日益重視物聯網 (IoT) 驅動的診斷生態系統、智慧基礎設施整合、互聯液態生物檢體平台和即時數據交換框架。這些措施充分利用了互聯的診斷設備、雲端資料平台和持續整合的真實世界證據 (RWE) 系統。例如，2026 年 1 月，專注於精準腫瘤學和液態生物檢體診斷的美國公司 Guardant Health 宣布與專注於腫瘤治療的美國製藥公司默克公司 (Merck & Co.) 建立多年戰略合作夥伴關係，利用 Guardant Infinity Smart 平台開發伴隨診斷產品並實現新型癌症治療方法的商業化。此次合作將 Guardant 的互聯液體和組織切片檢查檢測生態系統與默克公司的全球臨床開發基礎設施相結合，使診斷檢測能夠用作即時臨床試驗註冊工具。這將有助於持續監測生物標記，並支持伴隨診斷和標靶治療的全球商業化。

全球腫瘤分子診斷市場集中度很高，主要由幾家大型公司主導。截至2024年，前十名的競爭對手佔了41.95%的市場。

目錄

第1章：執行摘要

第2章 目錄

第3章表格一覽

第4章：圖表一覽

第5章：報告結構

第6章 市場特徵

  • 市場的一般定義
  • 概述
  • 腫瘤分子診斷市場：定義與細分
  • 市場區隔：依產品（儀器、試劑及其他產品）
  • 市場區隔：依技術分類（聚合酵素鏈鎖反應(PCR)、原位雜合反應(ISH)、恒溫核酸增幅(INNAT)、晶片與微陣列、定序、質譜、轉錄媒介增幅(TMA)、其他技術）
  • 市場區隔：按最終用戶分類（醫院、診斷中心、學術和研究機構以及其他最終用戶）

第7章 腫瘤分子診斷市場：主要產品與服務概述

  • 全球腫瘤分子診斷市場：吸引力評分及分析
    • 市場吸引力框架概述
    • 定量評估和調查方法
    • 市場吸引力評分的計算與解讀
    • 因素特定評估
    • 戰略洞察與建議

第8章：主要市場趨勢

  • 關鍵科技與未來趨勢
    • 數位化、雲端運算、巨量資料和網路安全
    • 物聯網 (IoT)、智慧基礎設施和互聯生態系統
    • 人工智慧和自主智慧
    • 工業4.0和智慧製造
    • 生物技術、基因組學和精準醫療
  • 主要趨勢
    • 擴展伴隨診斷和整合基因組分析生態系統
    • 綜合基因組分析和整合檢測平台的進展
    • RNA液態生物檢體和多體學分析平台的應用日益廣泛。
    • 基於液態生物檢體的綜合基因組分析的擴展

第9章 全球腫瘤分子診斷：成長與策略分析框架

  • 全球腫瘤分子診斷市場：PESTEL 分析
    • 政治的
    • 經濟的
    • 社會的
    • 技術的
    • 環境因素
    • 合法的
  • 最終用戶（B2B）分析
    • 醫院
    • 診斷中心
    • 學術研究機構
    • 其他最終用戶
  • 全球腫瘤分子診斷市場：規模與成長分析
  • 2020-2025年市場成長表現
    • 市場促進因素，2020-2025 年
    • 2020-2025年市場限制因素
  • 市場成長預測，2025-2030年，2035年
  • 預測成長要素和促進因素
    • 定量成長要素
    • 促進因素
    • 抑制因子

第10章：全球腫瘤分子診斷市場總潛在市場規模（TAM）分析

  • 總潛在市場（TAM）的定義與範圍
  • 調查方法和先決條件
    • 潛在市場總量：腫瘤分子診斷市場 - B2B
    • TAM比較分析

第11章 全球腫瘤分子診斷：市場區隔

  • 依產品
  • 透過技術
  • 最終用戶
  • 按類型細分：設備
  • 按類型細分：試劑
  • 按類型細分：其他產品

第12章：腫瘤分子診斷市場：區域與國家層級分析

第13章 亞太市場

第14章 東南亞市場

第15章 西歐市場

第16章：東歐市場

第17章：北美市場

第18章：南美洲市場

第19章 中東市場

第20章：非洲市場

第21章：競爭格局與公司概況

  • 2024年市場競爭格局及市場佔有率
  • 公司簡介
  • F. Hoffmann-La Roche AG（Company Overview, Products and Services, Business Strategy, Financial Overview）
  • Thermo Fisher Scientific Inc.（Company Overview, Products and Services, Business Strategy, Financial Overview）
  • Illumina Inc.（Company Overview, Products and Services, Business Strategy, Financial Overview）
  • Danaher Corp.（Company Overview, Products and Services, Business Strategy, Financial Overview）
  • Abbott Laboratories（Company Overview, Products and Services, Business Strategy, Financial Overview）

第22章 其他大型企業和創新企業

  • Siemens Healthcare AG（Company Overview, Products and Services）
  • QIAGEN NV（Company Overview, Products and Services）
  • Agilent Technologies（Company Overview, Products and Services）
  • Becton Dickinson and Company（Company Overview, Products and Services）
  • bioMerieux SA（Company Overview, Products and Services）
  • Bio-Rad Laboratories Inc.（Company Overview, Products and Services）
  • Sysmex Corporation（Company Overview, Products and Services）
  • Exact Sciences Corp.（Company Overview, Products and Services）
  • Guardant Health Inc.（Company Overview, Products and Services）
  • Biocartis Group NV（Company Overview, Products and Services）
  • Hologic Inc.（Company Overview, Products and Services）
  • Invitae Corporation（Company Overview, Products and Services）
  • NeoGenomics Laboratories, Inc.（Company Overview, Products and Services）
  • Myriad Genetics Inc.（Company Overview, Products and Services）
  • Tempus AI（Company Overview, Products and Services）

第23章：競爭標竿分析

第24章：競爭對手儀錶板

第25章：腫瘤分子診斷市場－公司評估矩陣

  • 創新與品牌領導者
  • 新興創新者
  • 品牌主導的傳統主義者
  • 利基市場或在地化追隨者公司

第26章：預計進入市場的新創企業

第27章 重大併購

  • LabGenomics USA Acquired Integrated Molecular Diagnostics（IMD）CLIA labs
  • Eurobio Scientific Acquired EndoPredict from Myriad Genetics
  • Quest Diagnostics Incorporated Acquired Haystack Oncology
  • Freenome Holdings Inc. Acquired Oncimmune Ltd

第28章 近期趨勢

  • 擴展基於蛋白質體學的精準診斷和人工智慧驅動的治療反應預測。
  • 利用NGS進行快速伴隨診斷與加速分散腫瘤分析

第29章 機遇與策略

  • 2030年全球腫瘤分子診斷市場：提供新機會的國家
  • 2030年全球腫瘤分子診斷市場：蘊藏新機會的細分市場
  • 2030年全球腫瘤分子診斷市場：成長策略
    • 基於市場趨勢的策略
    • 競爭對手的策略

第30章：腫瘤分子診斷市場：結論與建議

  • 結論
  • 推薦

第31章附錄

簡介目錄
Product Code: ME6MOMDO01_O26Q1

Oncology molecular diagnostics refers to a class of diagnostic tests and technologies that analyze genetic material, proteins, and other molecular biomarkers to detect, characterize, and monitor cancer. These diagnostics are used by healthcare providers, including oncologists, pathologists, and laboratory professionals, to identify specific mutations, gene expressions, and molecular signatures associated with different types of cancer.

The oncology molecular diagnostics market consists of sales by entities (organizations, sole traders and partnerships) of oncology molecular diagnostics that are utilized across various stages of cancer care, including early detection, diagnosis, prognosis, treatment selection, and monitoring of disease progression or recurrence. Oncology molecular diagnostics are often used when a patient presents symptoms suggestive of cancer, during routine screenings, or when selecting targeted therapies based on tumor genetics.

The global oncology molecular diagnostics market was valued at $3,202.6 million in 2020 which grew till 2025 at a compound annual growth rate (CAGR) of more than 11.0%.

Expansion Of Healthcare Infrastructure

During the historic period, the oncology molecular diagnostics market was driven by the expansion of healthcare infrastructure. As governments and healthcare organizations increasingly invested in strengthening healthcare systems, expanding diagnostic facilities, and improving access to advanced medical technologies, the adoption of molecular diagnostic solutions, including next-generation sequencing (NGS), liquid biopsy, and biomarker-based testing, expanded to support early cancer detection, accurate diagnosis, and personalized treatment planning. For instance, in May 2022, according to Australian Government, an official national authority responsible for public policy and healthcare system development, reported a record investment of $132 billion in the healthcare system for 2022-23, increasing to $140 billion by 2025-26, with a total commitment of $537 billion over the next four years, highlighting the growing focus on strengthening healthcare infrastructure and expanding access to advanced medical services. Therefore, the oncology molecular diagnostics market was driven by the expansion of healthcare infrastructure during the historic period.

Internet Of Things (IoT), Smart Infrastructure And Connected Ecosystems

Major companies in the oncology molecular diagnostics market are increasingly prioritizing Internet of Things (IoT)-enabled diagnostic ecosystems, smart infrastructure integration, connected liquid biopsy platforms, and real-time data exchange frameworks. These initiatives leverage interconnected diagnostic devices, cloud-based data platforms, and continuously integrated real-world evidence systems. For example, in January 2026, Guardant Health, a US-based company specializing in precision oncology and liquid biopsy diagnostics, announced a multi-year strategic collaboration with Merck & Co., a US-based pharmaceutical company specializing in oncology therapeutics, to develop companion diagnostics and commercialize new cancer therapies using the Guardant Infinity Smart platform, this collaboration integrates Guardant's connected liquid and tissue biopsy testing ecosystem with Merck's global clinical development infrastructure, enabling the use of diagnostic assays as real-time clinical trial enrollment tools, facilitating continuous biomarker monitoring, and supporting global commercialization of companion diagnostics and targeted therapies.

The global oncology molecular diagnostics market is concentrated, with large players operating in the market. The top 10 competitors in the market made up 41.95% of the total market in 2024.

Oncology Molecular Diagnostics Global Market Opportunities And Strategies To 2035 from The Business Research Company provides the strategists; marketers and senior management with the critical information they need to assess the global oncology molecular diagnostics market as it emerges from the COVID-19 shut down.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
  • Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market research findings.
  • Benchmark performance against key competitors.
  • Utilize the relationships between key data sets for superior strategizing.
  • Suitable for supporting your internal and external presentations with reliable high-quality data and analysis.

Where is the largest and fastest-growing market for oncology molecular diagnostics? How does the market relate to the overall economy; demography and other similar markets? What forces will shape the market going forward? The oncology molecular diagnostics market global report from The Business Research Company answers all these questions and many more.

The report covers market characteristics; size and growth; segmentation; regional and country breakdowns; competitive landscape; market shares; trends and strategies for this market. It traces the market's history and forecasts market growth by geography. It places the market within the context of the wider oncology molecular diagnostics; and compares it with other markets.

The report covers the following chapters

  • Introduction and Market Characteristics- Brief introduction to the segmentations covered in the market, definitions and explanations about the segments, key products and supply chain.
  • Key Trends- Highlights the major trends shaping the global market. This section also highlights likely future technologies and developments in the market.
  • Growth Analysis And Strategic Analysis Framework- Analysis on PESTEL, end use industries, market growth rate, global historic (2020-2025) and forecast (2025-2030, 2035F) market values and drivers and restraints that support and control the growth of the market in the historic and forecast periods, forecast growth contributors and total addressable market (TAM).
  • Global Market Size And Growth Global historic (2020-2025) and forecast (2025-2030, 2035F) market values and drivers and restraints that support and control the growth of the market in the historic and forecast periods.
  • Regional And Country Analysis- Historic (2020-2025) and forecast (2025-2030, 2035F) market values and growth and market share comparison by region and country.
  • Market Segmentation- Contains the market values (2020-2025) (2025-2030, 2035F) and analysis for each segment by product, by technology and by end user in the market. Historic (2020-2025) and forecast (2025-2030) and (2030-2035) market values and growth and market share comparison by region market.
  • Regional Market Size and Growth- Regional market size (2025), historic (2020-2025) and forecast (2025-2030, 2035F) market values and growth and market share comparison of countries within the region. This report includes information on all the regions Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa and major countries within each region.
  • Competitive Landscape- Details on the competitive landscape of the market, estimated market shares and company profiles of the leading players.
  • Other Major And Innovative Companies Details on the company profiles of other major and innovative companies in the market.
  • Competitive Benchmarking- Briefs on the financials comparison between major players in the market.
  • Competitive Dashboard- Briefs on competitive dashboard of major players.
  • Key Mergers and Acquisitions- Information on recent mergers and acquisitions in the market is covered in the report. This section gives key financial details of mergers and acquisitions which have shaped the market in recent years.
  • Recent Developments Information on recent developments in the market covered in the report.
  • Market Opportunities And Strategies Describes market opportunities and strategies based on findings of the research, with information on growth opportunities across countries, segments and strategies to be followed in those markets.
  • Conclusions And Recommendations- This section includes recommendations for oncology molecular diagnostics providers in terms of product/service offerings geographic expansion, marketing strategies and target groups.
  • Appendix- This section includes details on the NAICS codes covered, abbreviations and currencies codes used in this report.

Markets Covered:

  • 1) By Product: Instruments; Reagents; Other Products
  • 2) By Technology: Polymerase Chain Reaction (PCR); In-Situ Hybridization (ISH); Isothermic Nucleic Acid Amplification Technology (INNAT); Chips And Microarrays; Sequencing; Mass Spectroscopy; Transcription Mediated Amplification (TMA); Other Technologies
  • 3) By End User: Hospitals; Diagnostic Centers; Academic And Research Institutes; Other End Users
  • Companies Mentioned: F. Hoffmann-La Roche AG; Thermo Fisher Scientific Inc.; Illumina Inc.; Danaher Corp.; Abbott Laboratories
  • Countries: China; Australia; India; Indonesia; Taiwan; Japan; South Korea; USA; Germany; Italy; Spain; UK; France; Russia
  • Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time-series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets; GDP proportions; expenditure per capita; oncology molecular diagnostics indicators comparison.
  • Data segmentations: country and regional historic and forecast data; market share of competitors; market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Table of Contents

1 Executive Summary

  • 1.1 Dashboard

2 Table Of Contents

3 List Of Tables

4 List Of Figures

5 Report Structure

6 Market Characteristics

  • 6.1 General Market Definition
  • 6.2 Summary
  • 6.3 Oncology Molecular Diagnostics Market Definition And Segmentations
  • 6.4 Market Segmentation By Product (Instruments, Reagents And Other Products)
  • 6.5 Market Segmentation By Technology (Polymerase Chain Reaction (PCR), In-Situ Hybridization (ISH), Isothermic Nucleic Acid Amplification Technology (INNAT), Chips And Microarrays, Sequencing, Mass Spectroscopy, Transcription Mediated Amplification (TMA) And Other Technologies)
  • 6.6 Market Segmentation By End User (Hospitals, Diagnostic Centers, Academic And Research Institutes And Other End Users)

7 Oncology Molecular Diagnostics Market, Overview Of Key Products/Services

  • 7.1 Global Oncology Molecular Diagnostics Market Attractiveness Scoring And Analysis
    • 7.1.1 Overview Of Market Attractiveness Framework
    • 7.1.2 Quantitative Scoring Methodology
    • 7.1.3 Market Attractiveness Scoring And Interpretation
    • 7.1.4 Factor-Wise Evaluation
    • 7.1.5 Strategic Implications And Recommendations

8 Major Market Trends

  • 8.1 Key Technologies and Future Trends
    • 8.1.1 Digitalization, Cloud, Big Data And Cybersecurity
    • 8.1.2 Internet Of Things (IoT), Smart Infrastructure And Connected Ecosystems
    • 8.1.3 Artificial Intelligence And Autonomous Intelligence
    • 8.1.4 Industry 4.0 And Intelligent Manufacturing
    • 8.1.5 Biotechnology, Genomics And Precision Medicine
  • 8.2 Major Trends
    • 8.2.1 Expansion Of Companion Diagnostics And Integrated Genomic Profiling Ecosystems
    • 8.2.2 Advancement Of Comprehensive Genomic Profiling And Integrated Assay Platforms
    • 8.2.3 Rising Adoption Of RNA-Based Liquid Biopsy And Multiomic Profiling Platforms
    • 8.2.4 Expansion Of Liquid Biopsy-Based Comprehensive Genomic Profiling

9 Global Oncology Molecular Diagnostics Growth Analysis And Strategic Analysis Framework

  • 9.1 Global Oncology Molecular Diagnostics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
    • 9.1.1 Political
    • 9.1.2 Economic
    • 9.1.3 Social
    • 9.1.4 Technological
    • 9.1.5 Environmental
    • 9.1.6 Legal
  • 9.2 Analysis Of End User (B2B)
    • 9.2.1 Hospitals
    • 9.2.2 Diagnostic Centers
    • 9.2.3 Academic And Research Institutes
    • 9.2.4 Other End Users
  • 9.3 Global Oncology Molecular Diagnostics Market Size And Growth Analysis
  • 9.4 Historic Market Growth, 2020 - 2025, Value ($ Million)
    • 9.4.1 Market Drivers 2020 - 2025
    • 9.4.2 Market Restraints 2020 - 2025
  • 9.5 Forecast Market Growth, 2025 - 2030, 2035F Value ($ Million)
  • 9.6 Forecast Growth Contributors/Factors
    • 9.6.1 Quantitative Growth Contributors
    • 9.6.2 Drivers
    • 9.6.3 Restraints

10 Global Oncology Molecular Diagnostics Total Addressable Market (TAM) Analysis

  • 10.1 Definition And Scope of Total Addressable Market (TAM)
  • 10.2 Methodology And Assumptions
    • 10.2.1 Total Addressable Market for the Oncology Molecular Diagnostics Market - Business to Business (B2B)
    • 10.2.2 TAM Comparison Analysis

11 Global Oncology Molecular Diagnostics Market Segmentation

  • 11.1 Global Oncology Molecular Diagnostics Market, Segmentation By Product, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
  • 11.2 Global Oncology Molecular Diagnostics Market, Segmentation By Technology, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
  • 11.3 Global Oncology Molecular Diagnostics Market, Segmentation By End User, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
  • 11.4 Global Oncology Molecular Diagnostics Market, Sub Segmentation Of Instruments, By Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
  • 11.5 Global Oncology Molecular Diagnostics Market, Sub-Segmentation Of Reagents, By Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
  • 11.6 Global Oncology Molecular Diagnostics Market, Sub-Segmentation Of Other Products, By Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)

12 Oncology Molecular Diagnostics Market, Regional and Country Analysis

  • 12.1 Global Oncology Molecular Diagnostics Market, By Region, Historic and Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
  • 12.2 Global Oncology Molecular Diagnostics Market, By Country, Historic and Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)

13 Asia-Pacific Market

  • 13.1 Asia-Pacific Market Summary
    • 13.1.1 Market Overview (Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments And Major Companies)
  • 13.2 Asia-Pacific Oncology Molecular Diagnostics Market, Segmentation By Product, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
  • 13.3 Asia-Pacific Oncology Molecular Diagnostics Market, Segmentation By Technology, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
  • 13.4 Asia-Pacific Oncology Molecular Diagnostics Market, Segmentation By End User, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
  • 13.5 China Market
    • 13.5.1 China Market Summary
    • 13.5.2 Market Overview (Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments And Major Companies)
    • 13.5.3 China Oncology Molecular Diagnostics Market, Segmentation By Product, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
    • 13.5.4 China Oncology Molecular Diagnostics Market, Segmentation By Technology, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
    • 13.5.5 China Oncology Molecular Diagnostics Market, Segmentation By End User, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
  • 13.6 India Market
    • 13.6.1 India Oncology Molecular Diagnostics Market, Segmentation By Product, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
    • 13.6.2 India Oncology Molecular Diagnostics Market, Segmentation By Technology, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
    • 13.6.3 India Oncology Molecular Diagnostics Market, Segmentation By End User, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
  • 13.7 Japan Market
    • 13.7.1 Japan Market Summary
    • 13.7.2 Market Overview (Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments And Major Companies)
    • 13.7.3 Japan Oncology Molecular Diagnostics Market, Segmentation By Product, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
    • 13.7.4 Japan Oncology Molecular Diagnostics Market, Segmentation By Technology, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
    • 13.7.5 Japan Oncology Molecular Diagnostics Market, Segmentation By End User, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
  • 13.8 Australia Market
    • 13.8.1 Australia Oncology Molecular Diagnostics Market, Segmentation By Product, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
    • 13.8.2 Australia Oncology Molecular Diagnostics Market, Segmentation By Technology, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
    • 13.8.3 Australia Oncology Molecular Diagnostics Market, Segmentation By End User, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
  • 13.9 South Korea Market
    • 13.9.1 South Korea Market Summary
    • 13.9.2 Market Overview (Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments And Major Companies)
    • 13.9.3 South Korea Oncology Molecular Diagnostics Market, Segmentation By Product, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
    • 13.9.4 South Korea Oncology Molecular Diagnostics Market, Segmentation By Technology, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
    • 13.9.5 South Korea Oncology Molecular Diagnostics Market, Segmentation By End User, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
  • 13.10 Taiwan Market
    • 13.10.1 Taiwan Market Summary
    • 13.10.2 Market Overview (Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments And Major Companies)
    • 13.10.3 Taiwan Oncology Molecular Diagnostics Market, Segmentation By Product, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
    • 13.10.4 Taiwan Oncology Molecular Diagnostics Market, Segmentation By Technology, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
    • 13.10.5 Taiwan Oncology Molecular Diagnostics Market, Segmentation By End User, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)

14 South East Asia Market

  • 14.1 South East Asia Market Summary
  • 14.2 Market Overview (Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments And Major Companies)
  • 14.3 South East Asia Oncology Molecular Diagnostics Market, Segmentation By Product, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
  • 14.4 South East Asia Oncology Molecular Diagnostics Market, Segmentation By Technology, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
  • 14.5 South East Asia Oncology Molecular Diagnostics Market, Segmentation By End User, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
  • 14.6 Indonesia Market
    • 14.6.1 Indonesia Oncology Molecular Diagnostics Market, Segmentation By Product, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
    • 14.6.2 Indonesia Oncology Molecular Diagnostics Market, Segmentation By Technology, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
    • 14.6.3 Indonesia Oncology Molecular Diagnostics Market, Segmentation By End User, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)

15 Western Europe Market

  • 15.1 Western Europe Market Summary
  • 15.2 Market Overview (Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments And Major Companies)
  • 15.3 Western Europe Oncology Molecular Diagnostics Market, Segmentation By Product, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
  • 15.4 Western Europe Oncology Molecular Diagnostics Market, Segmentation By Technology, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
  • 15.5 Western Europe Oncology Molecular Diagnostics Market, Segmentation By End User, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
  • 15.6 UK Market
    • 15.6.1 UK Oncology Molecular Diagnostics Market, Segmentation By Product, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
    • 15.6.2 UK Oncology Molecular Diagnostics Market, Segmentation By Technology, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
    • 15.6.3 UK Oncology Molecular Diagnostics Market, Segmentation By End User, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
  • 15.7 Germany Market
    • 15.7.1 Germany Oncology Molecular Diagnostics Market, Segmentation By Product, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
    • 15.7.2 Germany Oncology Molecular Diagnostics Market, Segmentation By Technology, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
    • 15.7.3 Germany Oncology Molecular Diagnostics Market, Segmentation By End User, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
  • 15.8 France Market
    • 15.8.1 France Oncology Molecular Diagnostics Market, Segmentation By Product, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
    • 15.8.2 France Oncology Molecular Diagnostics Market, Segmentation By Technology, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
    • 15.8.3 France Oncology Molecular Diagnostics Market, Segmentation By End User, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
  • 15.9 Italy Market
    • 15.9.1 Italy Oncology Molecular Diagnostics Market, Segmentation By Product, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
    • 15.9.2 Italy Oncology Molecular Diagnostics Market, Segmentation By Technology, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
    • 15.9.3 Italy Oncology Molecular Diagnostics Market, Segmentation By End User, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
  • 15.10 Spain Market
    • 15.10.1 Spain Oncology Molecular Diagnostics Market, Segmentation By Product, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
    • 15.10.2 Spain Oncology Molecular Diagnostics Market, Segmentation By Technology, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
    • 15.10.3 Spain Oncology Molecular Diagnostics Market, Segmentation By End User, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)

16 Eastern Europe Market

  • 16.1 Eastern Europe Market Summary
  • 16.2 Market Overview (Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments And Major Companies)
  • 16.3 Eastern Europe Oncology Molecular Diagnostics Market, Segmentation By Product, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
  • 16.4 Eastern Europe Oncology Molecular Diagnostics Market, Segmentation By Technology, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
  • 16.5 Eastern Europe Oncology Molecular Diagnostics Market, Segmentation By End User, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
  • 16.6 Russia Market
    • 16.6.1 Russia Oncology Molecular Diagnostics Market, Segmentation By Product, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
    • 16.6.2 Russia Oncology Molecular Diagnostics Market, Segmentation By Technology, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
    • 16.6.3 Russia Oncology Molecular Diagnostics Market, Segmentation By End User, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)

17 North America Market

  • 17.1 North America Market Summary
  • 17.2 Market Overview (Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments And Major Companies)
  • 17.3 North America Oncology Molecular Diagnostics Market, Segmentation By Product, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
  • 17.4 North America Oncology Molecular Diagnostics Market, Segmentation By Technology, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
  • 17.5 North America Oncology Molecular Diagnostics Market, Segmentation By End User, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
  • 17.6 USA Market
    • 17.6.1 USA Market Summary
    • 17.6.2 Market Overview (Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments And Major Companies)
    • 17.6.3 USA Oncology Molecular Diagnostics Market, Segmentation By Product, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
    • 17.6.4 USA Oncology Molecular Diagnostics Market, Segmentation By Technology, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
    • 17.6.5 USA Oncology Molecular Diagnostics Market, Segmentation By End User, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
  • 17.7 Canada Market
    • 17.7.1 Canada Market Summary
    • 17.7.2 Market Overview (Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments And Major Companies)
    • 17.7.3 Canada Oncology Molecular Diagnostics Market, Segmentation By Product, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
    • 17.7.4 Canada Oncology Molecular Diagnostics Market, Segmentation By Technology, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
    • 17.7.5 Canada Oncology Molecular Diagnostics Market, Segmentation By End User, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)

18 South America Market

  • 18.1 South America Market Summary
  • 18.2 South America Oncology Molecular Diagnostics Market, Segmentation By Product, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
  • 18.3 South America Oncology Molecular Diagnostics Market, Segmentation By Technology, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
  • 18.4 South America Oncology Molecular Diagnostics Market, Segmentation By End User, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
  • 18.5 Brazil Market
    • 18.5.1 Brazil Oncology Molecular Diagnostics Market, Segmentation By Product, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
    • 18.5.2 Brazil Oncology Molecular Diagnostics Market, Segmentation By Technology, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
    • 18.5.3 Brazil Oncology Molecular Diagnostics Market, Segmentation By End User, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)

19 Middle East Market

  • 19.1 Middle East Market Summary
  • 19.2 Market Overview (Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments And Major Companies)
  • 19.3 Middle East Oncology Molecular Diagnostics Market, Segmentation By Technology, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
  • 19.4 Middle East Oncology Molecular Diagnostics Market, Segmentation By Product, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
  • 19.5 Middle East Oncology Molecular Diagnostics Market, Segmentation By End User, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)

20 Africa Market

  • 20.1 Africa Market Summary
  • 20.2 Market Overview (Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments And Major Companies)
  • 20.3 Africa Oncology Molecular Diagnostics Market, Segmentation By Product, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
  • 20.4 Africa Oncology Molecular Diagnostics Market, Segmentation By Technology, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
  • 20.5 Africa Oncology Molecular Diagnostics Market, Segmentation By End User, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)

21 Competitive Landscape And Company Profiles

  • 21.1 Oncology Molecular Diagnostics Market Competitive Landscape And & Market Share 2024
    • 21.1.1 Top 10 Companies (Ranked by revenue/share)
  • 21.2 Company Profiles
  • 21.3 F. Hoffmann-La Roche AG (Company Overview, Products and Services, Business Strategy, Financial Overview)
  • 21.4 Thermo Fisher Scientific Inc. (Company Overview, Products and Services, Business Strategy, Financial Overview)
  • 21.5 Illumina Inc. (Company Overview, Products and Services, Business Strategy, Financial Overview)
  • 21.6 Danaher Corp. (Company Overview, Products and Services, Business Strategy, Financial Overview)
  • 21.7 Abbott Laboratories (Company Overview, Products and Services, Business Strategy, Financial Overview)

22 Other Major And Innovative Companies

  • 22.1 Siemens Healthcare AG (Company Overview, Products and Services)
  • 22.2 QIAGEN N.V. (Company Overview, Products and Services)
  • 22.3 Agilent Technologies (Company Overview, Products and Services)
  • 22.4 Becton Dickinson and Company (Company Overview, Products and Services)
  • 22.5 bioMerieux SA (Company Overview, Products and Services)
  • 22.6 Bio-Rad Laboratories Inc. (Company Overview, Products and Services)
  • 22.7 Sysmex Corporation (Company Overview, Products and Services)
  • 22.8 Exact Sciences Corp. (Company Overview, Products and Services)
  • 22.9 Guardant Health Inc. (Company Overview, Products and Services)
  • 22.10 Biocartis Group NV (Company Overview, Products and Services)
  • 22.11 Hologic Inc. (Company Overview, Products and Services)
  • 22.12 Invitae Corporation (Company Overview, Products and Services)
  • 22.13 NeoGenomics Laboratories, Inc. (Company Overview, Products and Services)
  • 22.14 Myriad Genetics Inc. (Company Overview, Products and Services)
  • 22.15 Tempus AI (Company Overview, Products and Services)

23 Competitive Benchmarking

24 Competitive Dashboard

25 Oncology Molecular Diagnostics Market - Company Scoring Matrix

  • 25.1 Innovation & Brand Leaders
  • 25.2 Emerging Innovators
  • 25.3 Brand-Driven Traditionalists
  • 25.4 Niche or Local Followers

26 Upcoming Startups In the Market

27 Key Mergers And Acquisitions

  • 27.1 LabGenomics USA Acquired Integrated Molecular Diagnostics (IMD) CLIA labs
  • 27.2 Eurobio Scientific Acquired EndoPredict from Myriad Genetics
  • 27.3 Quest Diagnostics Incorporated Acquired Haystack Oncology
  • 27.4 Freenome Holdings Inc. Acquired Oncimmune Ltd

28 Recent Developments

  • 28.1 Expansion Of Proteomics-Based Precision Diagnostics And AI-Driven Treatment Response Prediction
  • 28.2 Acceleration Of Rapid NGS-Based Companion Diagnostics And Decentralized Tumor Profiling

29 Opportunities And Strategies

  • 29.1 Global Oncology Molecular Diagnostics Market In 2030 - Countries Offering Most New Opportunities
  • 29.2 Global Oncology Molecular Diagnostics Market In 2030 - Segments Offering Most New Opportunities
  • 29.3 Global Oncology Molecular Diagnostics Market In 2030 - Growth Strategies
    • 29.3.1 Market Trend Based Strategies
    • 29.3.2 Competitor Strategies

30 Oncology Molecular Diagnostics Market, Conclusions And Recommendations

  • 30.1 Conclusions
  • 30.2 Recommendations
    • 30.2.1 Product
    • 30.2.2 Place
    • 30.2.3 Price
    • 30.2.4 Promotion
    • 30.2.5 People

31 Appendix

  • 31.1 Geographies Covered
  • 31.2 Market Data Sources
  • 31.3 Research Methodology
  • 31.4 Currencies
  • 31.5 The Business Research Company
  • 31.6 Copyright and Disclaimer